Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions

Hemoglobin

Volumn 30, Issue 2, 2006, Pages 183-200

  Kontoghiorghes, George ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Anemia of chronic disease; Cancer; Deferiprone (L1); Deferoxamine (DFO); Iron mobilization; L1NAll; Non transferrin bound iron (NTBI); Thalassemia; Transferrin

Indexed keywords

1 ALLYL 2 METHYL 3 HYDROXYPYRID 4 ONE; CHELATING AGENT; CITRIC ACID; DEFERASIROX; DEFERIPRONE; DEFERITRIN; DEFEROXAMINE; NITRILOTRIACETIC ACID; PYRIDINE DERIVATIVE; TRANSFERRIN; UNCLASSIFIED DRUG;

ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CANCER; CHELATION THERAPY; CLINICAL PROTOCOL; CONFERENCE PAPER; HUMAN; IRON KINETICS; IRON METABOLISM; IRON OVERLOAD; THALASSEMIA;

ANEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHRONIC DISEASE; COMBINED MODALITY THERAPY; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN BINDING; PYRIDONES; RETICULOENDOTHELIAL SYSTEM; THALASSEMIA; TRANSFERRIN;

EID: 33745564177     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260600642450     Document Type: Conference Paper

References (33)

1. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003; 26(8):553-584.
2. Sargent PJ, Farnaud S, Evans RW. Structure/function overview of proteins involved in iron storage and transport. Curr Med Chem 2005; 12(23):2683-2693.
3. 3+ by transferrin. J Biol Chem 1975; 250(6):2182-2188.
4. 2+. J Biol Chem 1981; 256(23):12034-12039.
5. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK register. Lancet 2000; 355(9220):2051-2052.
6. Kyriacou K, Michaelides Y, Senkus R, Simamonian K, Pavlides N, Antoniades L, Zambartas C. Ultrastructural pathology of the heart in patients with β-thalassemia major. Ultastruct Pathol 2000; 24(2):75-81.
7. Hershko C, Bates GC, Bates BW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum fraction of potential toxicity. Br J Haematol 1978; 40(2):255-263.
8. Al-Refai FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in β-thalassemia patients treated with desferrioxamine and L1. Br J Haematol 1992; 82(2):431-436.
9. Craven CM, Alexander J, Eldridge M, Kushner JP, Bernstein S, Kaplan J. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc Natl Acad Sci USA 1987; 84(10):3457-3461.
10. Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem 2005; 12(23):2695-2709.
11. Kontoghiorghes GJ, Kolnagou A. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361(9352):184.
12. Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16):2161-2183.
13. Kontoghiorghes GJ. The design of orally active iron chelators for the treatment of thalassemia. PhD Thesis, University of Essex, Colchester, Essex, UK. British Library Microfilm No. D66194/86. 1982; 1-243.
14. Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L. Selection of a new generation of orally active α-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload. Am J Hematol 1993; 42(4):340-349.
15. Kontoghiorghes GJ. The study of iron mobilization from transferrin using α-ketohydroxy heteroaromatic chelators. Biochim Biophys Acta 1986; 869(2):141-146.
16. Pollack S, Aisen P, Lasky FD, Vanderhoff G. Chelate mediated transfer of iron from transferrin to desferrioxamine. Br J Haematol 1976; 34(2):231-235.
17. Kontoghiorghes GJ. Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 2005; 366(9488):804.
18. Kontoghiorghes GJ, Evans RW. Site specificity of iron removal from transferrin by α-kytohydroxypyridine chelators. FEBS Lett 1985; 189(1):141-144.
19. Evans RW, Sharma M, Ogwang W, Patel KJ, Bartlett AN, Kontoghiorghes GJ. The effect of α-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today 1992; 28(Suppl A):19-23.
20. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharm Ther 1990; 48(3):255-261.
21. Turcot I, Stintzi A, Xu J, Raymond KN. Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates. J Biol Inorg Chem 2000; 5(5):634-641.
22. Al-Refai FN, De Silva CE, Wonke B, Hoffbrand AV. Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload. J Clin Pathol 1995; 48(2):110-114.
23. Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Metals 1990; 3(1-2):183-187.
24. Forsbeck K, Nillson K, Kontoghiorghes GJ. Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K562 and U937 cell lines induced by chelators and their iron complexes. Eur J Haematol 1987; 39(4):318-325.
25. Blatt J, Taylor S, Kontoghiorghes GJ. Comparison of antineuroblastoma activity of desferrioxamine with that of oral iron chelators. Cancer Res 1989; 49(11):2925-2927.
26. Kontoghiorghes GJ, Piga A, Hoffbrand AV. Cytotoxic and DNA inhibitory effects of iron chelators on human leukaemic cell lines. Haematol Oncol 1986; 4(3):195-204.
27. Richardson DR. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem 2005; 12(23):2711-2730.
28. Vreugdenhil G, Kontoghiorghes GJ, van Eijk HG, Swaak AJG. Impaired erythropoietin responsiveness to the anemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Exp Rheumatol 1991; 9(1):35-40.
29. Giordano N, Fioravanti A, Sancasciani S, Marcolongo R. Increased storage of iron and anaemia in rheumatoid arthritis: usefulness of desferrioxamine. Br Med J 1984; 289(6450):961-962.
30. Kontoghiorghes GJ, Barr J, Baillod RA. Studies of aluminium mobilisation in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid- 4-one. Arzn.Forsch/Drug Res 1994; 44(4):522-526.
31. Kontoghiorghes GJ, Weinberg ED. Iron: mammalian defense systems, mechanisms of disease and chelation therapy approaches. Blood Rev 1995; 9(1):33-46.
32. Pootrakul P, Josephson B, Huebers HA, Finch CA. Quantitation of ferritin iron in plasma, an explanation for non-transferrin iron. Blood 1988; 71(4):1120-1123.
33. Kontoghiorghes GJ. Decreased solubilisation of ferritin iron and fresh iron (III) precipitate following repeated chelator treatments. Inorg Chim Acta 1987; 138:36-40.